Serum level of interleukin-17 in patients with psoriasis, before and after treatment

Completed

• Conditions: Serum level of IL-17, as a pro-inflammatory cytokine, is higher in patients with psoriasis. Additionally, treatment of psoriasis with topical medications reduce serum level of IL-17.; psoriasis; interleukin-17

• Registration Number: TCTR20220404002
• Lead Sponsor: Hamadan University of Medical sciences

Brief Summary

The mean serum levels of IL-17 were significantly higher in patients than in healthy controls. Also, treatment of psoriasis with topical medications reduced serum level of IL-17 and severity of disease, which reflecting the value of IL-17 as a biomarker in assessment of response to treatment.

Detailed Description

Not available

Study Timeline

• Study Completion: 2021-03-01
• Study Start: 2022-04-04
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Patients with psoriasis referred to dermatology clinic were selected based on definite clinical and pathological criteria. The patients should have active psoriatic skin lesions and a history of disease, without recent use of topical or systemic corticosteroid in the last three months. Healthy subjects (the control group) were selected from non-familial companions referred to the clinic if they had no history of autoimmune or inflammatory diseases.

Exclusion Criteria

Subjects with a history of concomitant autoimmune or inflammatory diseases, as well as pregnant or lactating women were excluded.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Disease severity 4 weeks PASI (Psoriasis Area and Severity Index)

Secondary Outcome Measures

Name	Time	Method
/A N/A N/A